KLS:7148
Duopharma Biotech Berhad · KLS · Healthcare · MYR · FY for 2025
Figures on this page computed 2026-11-08 12:05 UTC
Last close
n/aMYR
Market data
We are not showing closes for this listing. A line drawn through points we do not hold would look exactly like a listing that did not move.
12.2xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
9.4%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
9.2%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
3.1%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- computed
6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
Five bars, one line
lens 7 of 9Each against its own average
4 of 5 readExcept where said otherwise: Computed from the filing for 2025
- Sales1.50x
Its own average over 10 years, 621.2M.
- Profit1.54x
Its own average over 10 years, 56.9M.
- Free cash flow18.60x
Its own average over 10 years, 4.6M.
- Debt1.43x
Its own average over 10 years, 344.7M.
- Pricen/a
Its own average over 0 years. Market data
Free cash flow is furthest from its own average, at 18.60 times.
The filed years, as a table
10Each line is 100 at 2016-12-31, the first year we hold.
| Filed year | Sales | Profit | Shares in issue |
|---|---|---|---|
| 2016-12-31 | 100.0 | 100.0 | 100.0 |
| 2017-12-31 | 149.5 | 158.3 | 100.0 |
| 2018-12-31 | 159.4 | 177.6 | 100.8 |
| 2019-12-31 | 184.2 | 206.0 | 103.0 |
| 2020-12-31 | 182.1 | 218.5 | 106.4 |
| 2021-12-31 | 204.2 | 244.8 | 107.0 |
| 2022-12-31 | 222.6 | 261.4 | 109.3 |
| 2023-12-31 | 225.2 | 196.2 | 110.5 |
| 2024-12-31 | 260.0 | 233.5 | 110.8 |
| 2025-12-31 | 297.7 | 326.0 | 110.8 |
How sales was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- MYR
How profit was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- MYR
How shares in issue was got
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- MYR
Figures behind the shape
Growth
10.3%faster is higher, placed against 4,950 companies as of 2026-11-07
Five-year revenue growth rate10.3%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- computed
Five-year EPS growth rate7.4%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- computed
One-year change in net income39.6%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- computed
Returns on capital
11.5%higher is higher, placed against 5,089 companies as of 2026-11-07
Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on equity11.5%
Net Income / Shareholders' Equity x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
Return on assets6.0%
Net Income / Total Assets x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
Margins
39.0%wider is higher, placed against 3,412 companies as of 2026-11-07
Gross margin39.0%
Gross Profit / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
Operating margin15.7%
Operating Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
Net margin9.4%
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
Free cash flow margin9.2%
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
Price
12.2xcheaper is higher, placed against 4,362 companies as of 2026-11-07
Price to earnings12.2x
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- computed
- Computed from the filing for 2025
Price to book1.4x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- computed
- Computed from the filing for 2025
- computed
- Computed from the filing for 2025
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Price to sales ratio1.1x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- computed
- Computed from the filing for 2025
- Computed from the filing for 2025
Safety
2.61safer is higher, placed against 3,227 companies as of 2026-11-07
Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
Current ratio2.61
Current Assets / Current Liabilities
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
Interest coverage5.9x
Operating Income / Interest Expense
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
Altman Z-Score2.72
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
What it pays out
3.1%more, and better covered, is higher, placed against 1,091 companies as of 2026-11-07
Dividend yield3.1%
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- computed
Payout ratio38.5%
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
Dividend cover ratio2.5x
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- MYR
- computed
Share a finding
A link to the finding, not to you: it carries nothing about your account.